Facial Aesthetics (Botox, Dermal Fillers, Collagen Products)

• Publication date: March 2011

The report provides industry landscape, competitive landscape and industry trends data on the facial aesthetics industry . The report provides comprehensive data on the major industry developments affecting the industry, and key analytical content on the industry dynamics. The report also reviews the competitive landscape and technology offerings. Scope of the Research - Key geographies covered include the US, the UK, G...

The report provides industry landscape, competitive landscape and industry trends data on the facial aesthetics industry . The report provides comprehensive data on the major industry developments affecting the industry, and key analytical content on the industry dynamics. The report also reviews the competitive landscape and technology offerings.


Scope of the Research

- Key geographies covered include the US, the UK, Germany, France, Italy, Spain, Japan, China, India, Australia, and Brazil.
- Key sectors covered include botulinum toxin, hyaluronic acid, particle and polymer fillers, and collagens.
- Annualized industry revenues data for 2010, projection forward for 7 years to 2017. Firms shares data for 2010.
- Qualitative analysis of key industry trends, industry drivers, and restraints by each category within facial aesthetics industry .
- The report also covers data on the leading industry players, the competitive landscape, and the leading new product development and technologies.
- Key Companies covered include Allergan, Q-Med AB, Mentor Corporation, Medicis and BioForm Medical.

Why Should You Get This Report?

- Develop business strategies by understanding the trends and developments that are driving the facial aesthetics industry globally.
- Design and develop your product development, industry ing and sales strategies.
- Develop successful market-entry strategies .
- Identify key players best positioned to take advantage of the emerging industry opportunities.
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return.
- What’s the next big thing in the facial aesthetics industry landscape? – Identify, understand and decide.
- Make more informed business decisions from the insightful and in-depth analysis of the global facial aesthetics industry and the factors shaping it.

Global Skin Care Products Industry

1 Table of contents

I Table of contents 1
I. 1 List of Data tables 3
I. 2 List of Charts 4

II Executive Summary 5

III Introduction 8
III. 1 GlobalData Report Guidance 8

IV Facial Aesthetics – Device Overview 9
IV. 1 Botulinum Toxin 9
IV. 2 Hyaluronic Acid Based Dermal Fillers 9
IV. 3 Particle and Polymer Based Dermal Fillers 9
IV. 4 Collagen Products 9

V Facial Aesthetics, March ket Characterization 10
V. 1 Facial Aesthetics March ket, Global, Sales (USD Million), Forecasted data, from 2010 to 2016 10
V. 2 Facial Aesthetics March ket, Key Trends 10
V. 2.1 Hyaluronic Acid Based Dermal Fillers to Drive the March ket for Facial Aesthetics in the Future 10
V. 2.2 Dermal Fillers Derived from March ine Algae are Expected to Drive Future Growth in the Facial Aesthetics March ket 11
V. 3 Facial Aesthetics, March ket Dynamics 11
V. 3.1 March ket Drivers 11
V. 3.2 March ket Restraints 13

VI Facial Aesthetics March ket – Segment Analysis 14
VI. 1 Botulinum Toxin, Global, Sales (USD Million), Forecasted data, 2010–2017 14
VI. 2 Botulinum Toxin, March ket Dynamics 15
VI. 2.1 Increasing Number of Procedures and Reducing Price Trend to be the Key Drivers for Increasing Botulinum Toxin Procedures 15
VI. 2.2 High Side Effects Profile and Temporary Results are the Major Restraints for the Growth of Botulinum Toxin March ket 16
VI. 3 Hyaluronic Acid Based Dermal Fillers, Global, Sales (USD Million), Forecasted data, 2010–2017 16
VI. 4 Hyaluronic Acid Based Dermal Fillers, March ket Dynamics 17
VI. 4.1 Low Side Effects Profile and Recurring Sales due to Multiple Treatments to be the Key Drivers for Growth in Procedures Using Hyaluronic Acid Based Dermal Fillers 17
VI. 4.2 Increasing Preference for Botulinum Toxin is the Major Restraint for Hyaluronic Acid Based Dermal Fillers 18
VI. 5 Particle and Polymer Fillers, Global, Sales (USD Million), Forecasted data, 2010–2017 18
VI. 6 Particle and Polymer Based Dermal Fillers, March ket Dynamics 19
VI. 6.1 Long Term Results, the Key Driver for Increase in Procedures Using Particle and Polymer Based Dermal Fillers 19
VI. 6.2 High Side Effects Profile and Cost is a Major Restraint for the Growth of Particle and Polymer Fillers March ket 20
VI. 7 Collagen Products, Global, Sales (USD Million), Forecasted data, from 2010 to 2017 20
VI. 8 Collagen Products, March ket Dynamics 21
VI. 8.1 Increasing Preference for Hyaluronic Acid Based Dermal Fillers has led to the December line of Collagen Products 21

VII Facial Aesthetics March ket, by Country, 2010–2017 22
VII. 1 Facial Aesthetics March ket, the US, Sales (USD Million), Forecasted data, 2010–2017 22
VII. 2 Facial Aesthetics March ket, the UK, Sales (USD Million), Forecasted data, 2010–2017 24
VII. 3 Facial Aesthetics March ket, Germany, Sales (USD Million), Forecasted data, 2010–2017 26
VII. 4 Facial Aesthetics March ket, France, Sales (USD Million), Forecasted data, 2010–2017 28
VII. 5 Facial Aesthetics March ket, Italy, Sales (USD Million), Forecasted data, 2010–2017 30
VII. 6 Facial Aesthetics March ket, Spain, Sales (USD Million), Forecasted data, 2010–2017 32
VII. 7 Facial Aesthetics March ket, Japan, Sales (USD Million), Forecasted data, 2010–2017 34
VII. 8 Facial Aesthetics March ket, China, Sales (USD Million), Forecasted data, 2010–2017 36
VII. 9 Facial Aesthetics March ket, India, Sales (USD Million), Forecasted data, 2010–2017 38
VII. 10 Facial Aesthetics March ket, Australia, Sales (USD Million), Forecasted data, 2010–2017 40
VII. 11 Facial Aesthetics March ket, Brazil, Sales (USD Million), Forecasted data, 2010–2017 42

VIII Facial Aesthetics March ket – Strategic Competitive Assessment 44
VIII. 1 Facial Aesthetics March ket, the US, Market Shares, 2010 44
VIII. 2 Facial Aesthetics March ket, Europe, Market Shares, 2010 45
VIII. 3 Facial Aesthetics March ket, Asia-Pacific, Market Shares, 2010 46
VIII. 4 Facial Aesthetics March ket, Key March ket Participants 48
VIII. 4.1 Allergan, Inc 48
VIII. 4.2 Q–Med AB 50
VIII. 4.3 Mentor Corporation 51
VIII. 4.4 Medicis Pharmaceuticals Corporation 54
VIII. 4.5 BioForm Medical, Inc 55

IX Facial Aesthetics March ket – Strategic Pipeline Assessment 58
IX. 1 Facial Aesthetics March ket, Pipeline Assessment, by Development Stage 58
IX. 2 Profiles of Pipeline Products in Facial Aesthetics March ket 61
IX. 2.1 Contura International A/S: Aquamid 61
IX. 2.2 Celltrix AB: Credurance 61
IX. 2.3 Albiorex: Humallagen Dermal Filler 61
IX. 2.4 Allergan, Inc.: Juvederm Voluma 62
IX. 2.5 Q-Med AB: Macrolane 62
IX. 2.6 Genzyme Corporation: NADGL 63
IX. 2.7 Anika Therapeutics, Inc.: Next Generation ELEVESS Dermal Filler 63
IX. 2.8 Merz GmbH & Co. KGaA: November abel-Dermal Bead 63
IX. 2.9 Prollenium Medical Technologies, Inc: Revanesse Ultra 64
IX. 2.10 JUVENIS LTD.: Tenergel 64
IX. 2.11 FibroGen, Inc.: FG-5030 64
IX. 2.12 TEI Biosciences Inc.: Injectable Dermal Filler 65
IX. 2.13 Revance Therapeutics, Inc.: RT001 65
IX. 2.14 Merz Pharmaceuticals Inc.: NT-201 65

X Appendix 66
X. 1 Definitions 66
X. 1.1 Facial Aesthetics 66
X. 2 Acronyms 66
X. 3 Sources 67
X. 4 Research Methodology 67
X. 5 Secondary Research 67
X. 6 Primary Research 67
X. 7 Models 68
X. 8 Forecasted data s 68
X. 9 Expert Panels 68
X. 10 GlobalData Consulting 68
X. 11 Contact Us 69
X. 12 Disclaimer 69

1.1 List of Data tables
Data table 1: Facial Aesthetics March ket, Global, Sales (USD Million), 2010–2017 10
Data table 2: Botulinum Toxin, Global, Sales (USD Million), 2010–2017 14
Data table 3: Botulinum Toxin March ket, Global, Procedures (million), 2010–2017 15
Data table 4: Hyaluronic Acid Based Dermal Fillers, Global, Sales (USD Million), 2010–2017 16
Data table 5: Hyaluronic Acid Based Dermal Fillers March ket, Global, Procedures (million), 2010–2017 17
Data table 6: Particle and Polymer Fillers, Global, Sales (USD Million), 2010–2017 18
Data table 7: Particle and Polymer Based Dermal Fillers March ket, Global, Procedures (000’s), 2010–2017 19
Data table 8: Collagen Products, Global, Sales (USD Million), 2010–2017 20
Data table 9: Facial Aesthetics March ket, the US, Sales (USD Million), 2010–2017 22
Data table 10: Facial Aesthetics March ket, the US, Procedures (000’s), 2010 23
Data table 11: Facial Aesthetics March ket, the UK, Sales (USD Million), 2010–2017 24
Data table 12: Facial Aesthetics March ket, the UK, Procedures (000’s), 2010 25
Data table 13: Facial Aesthetics March ket, Germany, Sales (USD Million), 2010–2017 26
Data table 14: Facial Aesthetics March ket, Germany, Procedures (000’s), 2010 27
Data table 15: Facial Aesthetics March ket, France, Sales (USD Million), 2010–2017 28
Data table 16: Facial Aesthetics March ket, France, Procedures (000’s), 2010 29
Data table 17: Facial Aesthetics March ket, Italy, Sales (USD Million), 2010–2017 30
Data table 18: Facial Aesthetics March ket, Italy, Procedures (000’s), 2010 31
Data table 19: Facial Aesthetics March ket, Spain, Sales (USD Million), 2010–2017 32
Data table 20: Facial Aesthetics March ket, Spain, Procedures (000’s), 2010 33
Data table 21: Facial Aesthetics March ket, Japan, Sales (USD Million), 2010–2017 34
Data table 22: Facial Aesthetics March ket, Japan, Procedures (000’s), 2010 35
Data table 23: Facial Aesthetics March ket, China, Sales (USD Million), 2010–2017 36
Data table 24: Facial Aesthetics March ket, China, Procedures (000’s), 2010 37
Data table 25: Facial Aesthetics March ket, India, Sales (USD Million), 2010–2017 38
Data table 26: Facial Aesthetics March ket, India, Procedures (000’s), 2010 39
Data table 27: Facial Aesthetics March ket, Australia, Sales (USD Million), 2010–2017 40
Data table 28: Facial Aesthetics March ket, Australia, Procedures (000’s), 2010 41
Data table 29: Facial Aesthetics March ket, Brazil, Sales (USD Million), 2010–2017 42
Data table 30: Facial Aesthetics March ket, Brazil, Procedures (000’s), 2010 43
Data table 31: Facial Aesthetics March ket, the US, Market Shares, Sales (USD Million), 2010 44
Data table 32: Facial Aesthetics March ket, Europe, Market Shares, Sales (USD Million), 2010 45
Data table 33: Facial Aesthetics March ket, Asia-Pacific, Market Shares, Sales (USD Million), 2010 46
Data table 34: Allergan, March keted Products, Applications, Features and Benefits, 2010 49
Data table 35: Allergan Inc., Takes Over Groupe Corneal Laboratories SA, 2007 49
Data table 36: Q–Med AB, March keted Products, Applications, Features and Benefits, 2010 50
Data table 37: Galderma to Acquire Q–Med AB, 2010 50
Data table 38: Mentor Corporation, March keted Products, Applications, Features and Benefits, 2010 52
Data table 39: Johnson & Johnson Takes Over Mentor Corporation, 2009 52
Data table 40: Medicis, March keted Products, Applications, Features and Benefits, 2010 54
Data table 41: BioForm Medical, March keted Products, Applications, Features and Benefits, 2010 55
Data table 42: Merz Pharma Completes The Acquisition of BioForm Medical, 2010 57
Data table 43: Facial Aesthetics March ket, List of Pipeline Products, Global, 2010 60
Data table 44: Aquamid, Product Status 61
Data table 45: Credurance, Product Status 61
Data table 46: Humallagen Dermal Filler, Product Status 62
Data table 47: Juvederm Voluma, Product Status 62
Data table 48: Macrolane, Product Status 62
Data table 49: NADGL, Product Status 63
Data table 50: Next Generation ELEVESS Dermal Filler, Product Status 63
Data table 51: November abel–Dermal Bead, Product Status 63
Data table 52: Revanesse Ultra, Product Status 64
Data table 53: November abel–Dermal Bead, Product Status 64
Data table 54: FG-5030, Product Status 64
Data table 55: Injectable Dermal Filler, Product Status 65
Data table 56: RT001, Product Status 65
Data table 57: NT-201, Product Status 65

1.2 List of Charts

Chart 1: Facial Aesthetics March ket, Global, Sales (USD Million), 2010–2017 10
Chart 2: Facial Aesthetics March ket, March ket Dynamics 11
Chart 3: Botulinum Toxin, Global, Sales (USD Million), 2010–2017 14
Chart 4: Botulinum Toxin March ket, Global, Procedures (million), 2010–2017 15
Chart 5: Hyaluronic Acid Based Dermal Fillers, Global, Sales (USD Million), 2010–2017 16
Chart 6: Hyaluronic Acid Based Dermal Fillers March ket, Global, Procedures (million), 2010–2017 17
Chart 7: Particle and Polymer Fillers, Global, Sales (USD Million), 2010–2017 18
Chart 8: Particle and Polymer Based Dermal Fillers March ket, Global, Procedures (000’s), 2010–2017 19
Chart 9: Collagen Products, Global, Sales (USD Million), 2010–2017 20
Chart 10: Facial Aesthetics March ket, the US, Sales (USD Million), 2010–2017 22
Chart 11: Facial Aesthetics March ket, the US, Procedures (000’s), 2010 23
Chart 12: Facial Aesthetics March ket, the UK, Sales (USD Million), 2010–2017 24
Chart 13: Facial Aesthetics March ket, the UK, Procedures (000’s), 2010 25
Chart 14: Facial Aesthetics March ket, Germany, Sales (USD Million), 2010–2017 26
Chart 15: Facial Aesthetics March ket, Germany, Procedures (000’s), 2010 27
Chart 16: Facial Aesthetics March ket, France, Sales (USD Million), 2010–2017 28
Chart 17: Facial Aesthetics March ket, France, Procedures (000’s), 2010 29
Chart 18: Facial Aesthetics March ket, Italy, Sales (USD Million), 2010–2017 30
Chart 19: Facial Aesthetics March ket, Italy, Procedures (000’s), 2010 31
Chart 20: Facial Aesthetics March ket, Spain, Sales (USD Million), 2010–2017 32
Chart 21: Facial Aesthetics March ket, Spain, Procedures (000’s), 2010 33
Chart 22: Facial Aesthetics March ket, Japan, Sales (USD Million), 2010–2017 34
Chart 23: Facial Aesthetics March ket, Japan, Procedures (000’s), 2010 35
Chart 24: Facial Aesthetics March ket, China, Sales (USD Million), 2010–2017 36
Chart 25: Facial Aesthetics March ket, China, Procedures (000’s), 2010 37
Chart 26: Facial Aesthetics March ket, India, Sales (USD Million), 2010–2017 38
Chart 27: Facial Aesthetics March ket, India, Procedures (000’s), 2010 39
Chart 28: Facial Aesthetics March ket, Australia, Sales (USD Million), 2010–2017 40
Chart 29: Facial Aesthetics March ket, Australia, Procedures (000’s), 2010 41
Chart 30: Facial Aesthetics March ket, Brazil, Sales (USD Million), 2010–2017 42
Chart 31: Facial Aesthetics March ket, Brazil, Procedures (000’s), 2010 43
Chart 32: Facial Aesthetics March ket, the US, Market Shares, 2010 44
Chart 33: Facial Aesthetics March ket, Europe, Market Shares, 2010 45
Chart 34: Facial Aesthetics March ket, Asia-Pacific, Market Shares, 2010 46
Chart 35: Botulinum Toxin Product Benchmarking 46
Chart 36: Hyaluronic Acid Based Dermal Fillers Product Benchmarking 47
Chart 37: Allergan, Inc. SWOT 48
Chart 38: Q-Med AB, SWOT 50
Chart 39: Mentor Corporation, SWOT 51
Chart 40: Medicis Pharmaceutical Corporation, SWOT 54
Chart 41: BioForm Medical, Inc., SWOT 56
Chart 42: Facial Aesthetics March ket, Pipeline Assessment, by Development Stage 58
Chart 43: Facial Aesthetics March ket, Pipeline Assessment, by Unmet Need 59Allergan, Inc
Q–Med AB
Mentor Corporation
Medicis Pharmaceuticals Corporation
BioForm Medical, Inc